EN
icon
CN
CN | EN
技术平台
岸迈生物具有自主知识产权的双抗技术平台
广泛地适用于多种靶点
与单抗相似的生产便利
性和工艺放大能力
与单抗相似的药代动力学
特性以及免疫原性
保留单抗的结合功能和
亲和力
与单抗相当的可溶性及
稳定性
基于稳定细胞株能快速
进行产业化
产品管线
EpimAb拥有强大和可持续的产品管线,目前有4个临床项目 ( EMB-01、EMB-02、EMB-06和EMB-09 ) 以及10多个临床前候选药物。专有的双特异性平台FIT-Ig®使EpimAb能够精准覆盖三个战略肿瘤学领域 ( 肿瘤靶向、双免疫检查点、免疫细胞导向 ),并保持推动更多临床前项目进入临床的强劲势头。
EMB-02
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.
EGFR/cMET in NSCLC, Monotherapy
EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.
EGFR/cMET in NSCLC, Combo with Tagrisso®
EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.
EGFR/cMET in GI Cancers, Monotherapy
EMB-02
EMB-02 is a bispecific antibody targeting human programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) and is being evaluated in advanced solid tumors. This antibody is designed to target human PD-1 and LAG-3 concomitantly or independently and disrupt the immune suppression mediated by both pathways, thereby restoring T-cell effector function and enhancing anti-cancer activity. Currently, a global Phase I/II study is ongoing with sites opened in US, Australia, and China.
PD-1/LAG-3 in Solid Tumor
EMB-06
EMB-06 is a recombinant humanized bispecific antibody targeted against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding to BCMA on tumor cell surface, EMB-06 can recruit and activate CD3 expressing T lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor cells. Currently, a global Phase I/II study is enrolling patients in Australia and China.
BCMA/CD3 in Multiple Myeloma
EMB-09
EMB-09 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to block PD-1/PD-L1 inhibitory signaling, and conditionally activate T effector cells by stimulating OX40 through PD-L1 dependent cross linking. EMB-09 showed superior immune cell activation in comparison with the mAb combinations. Its unique OX40 binding epitope could improve the therapeutic window, and silenced Fc effector function can avoid T effector cell depletion.
PD-L1/OX40 in Solid Tumor
EMB-07
EMB-07 is a T cell redirecting bispecific antibody by targeting a novel tumor associated antigen (ROR1) and cluster of differentiation 3 (CD3). EMB-07 is designed based on EpimAb’s proprietary bispecific antibody platform. Upon binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3 expressing T lymphocytes, thereby promoting the cytotoxic effect of T lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile. IND submission is expected in 2022.
ROR1/CD3 in Solid Tumor & Hematologic Malignancies
News
2024-03-06
EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical Results of EMB-07 at the 2024 American Association for Cancer Research Annual Meeting
2023-11-01
EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting
2023-10-12
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement
关于岸迈
岸迈生物是一家创新型国际化生物技术企业,在上海和苏州分别设有研发中心和GMP生产基地,专注于利用自主知识产权的双特异性抗体技术平台FIT-Ig®进行创新生物药的研究和开发。基于FIT-Ig®平台技术,岸迈生物正在针对免疫肿瘤和其他临床需求高的领域进行双特异性抗体系列原创产品的开发。岸迈生物同时也在通过全球范围内的技术授权、合作开发等多种形式实现平台的战略发展和产品多元化布局。
联系我们
上海
地址
中国上海市张江高科技园区中科路702号金创大厦2栋6楼
邮编:201204
邮箱
contact@epimab.com
苏州
地址
中国苏州工业园区桑田街218号19号楼
邮编:215128
邮箱
contact@epimab.com
undefined
上海
苏州